RevOpsis treatment, an innovative biopharmaceutical company focused on eye treatments, has announced the successful closing of its first seed funding round, raising $16.5 million. The funding will advance the development and commercialization of treatments for chronic multifactorial diseases through RevOpsis' proprietary Rev-Mod platform.

Of the total amount raised, $7.5 million comes from non-dilutive capital sources. The funds will support the completion of an Investigational New Drug (IND) lead study for RO-104, RevOpsis' lead candidate for the treatment of neovascular age-related macular degeneration (nAMD). The financing will also facilitate the initiation of first-in-human clinical trials for RO-104 and the ongoing discovery and development of the RevOpsis pipeline. Additionally, the Company intends to use the funding to hire key management personnel to further its objectives.

Neovascular AMD represents a significant opportunity in the retinal disease space, which is expected to affect an estimated four million patients over the next five years. In 2023, the global revenue of anti-VEGF-A inhibitors, a common treatment for NAMD, will reach approximately $9 billion. However, significant unmet needs remain in terms of vision improvement and treatment burden.

RO-104 is a novel tri-specific biologic designed to target all three dominant angiogenic pathways involved in extrinsic retinal diseases such as NAMD. It has the potential to be the first monotherapy agent capable of enhancing visual outcomes and prolonging disease remission in NAMD patients.

The seed funding round includes strategic investment from leading organizations in contract development and manufacturing, ophthalmic drug and device development, as well as private and angel investors, including prominent retinal specialists. This financial milestone puts RevOpsis in a position to begin a first-in-human study with RO-104 by 2025.

Dr. Ram Bhandari, Interim CEO of RevOpsis, thanked the investors for their support and emphasized the importance of this funding in advancing the company's mission to deliver innovative therapeutics to patients worldwide. With this infusion of capital, RevOpsis is poised to advance its lead candidate development and advance its pipeline research efforts.